Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

456 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Pancreatic cancer: Update on immunotherapies and algenpantucel-L.
McCormick KA, Coveler AL, Rossi GR, Vahanian NN, Link C, Chiorean EG. McCormick KA, et al. Among authors: link c. Hum Vaccin Immunother. 2016 Mar 3;12(3):563-75. doi: 10.1080/21645515.2015.1093264. Hum Vaccin Immunother. 2016. PMID: 26619245 Free PMC article. Review.
Algenpantucel-L immunotherapy in pancreatic adenocarcinoma.
Coveler AL, Rossi GR, Vahanian NN, Link C, Chiorean EG. Coveler AL, et al. Among authors: link c. Immunotherapy. 2016 Feb;8(2):117-25. doi: 10.2217/imt.15.113. Epub 2016 Jan 20. Immunotherapy. 2016. PMID: 26787078 Review.
A Phase 3 Randomized Clinical Trial of Chemotherapy With or Without Algenpantucel-L (HyperAcute-Pancreas) Immunotherapy in Subjects With Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer.
Hewitt DB, Nissen N, Hatoum H, Musher B, Seng J, Coveler AL, Al-Rajabi R, Yeo CJ, Leiby B, Banks J, Balducci L, Vaccaro G, LoConte N, George TJ, Brenner W, Elquza E, Vahanian N, Rossi G, Kennedy E, Link C, Lavu H. Hewitt DB, et al. Among authors: link c. Ann Surg. 2022 Jan 1;275(1):45-53. doi: 10.1097/SLA.0000000000004669. Ann Surg. 2022. PMID: 33630475 Clinical Trial.
A Phase I Study of Alpha-1,3-Galactosyltransferase-Expressing Allogeneic Renal Cell Carcinoma Immunotherapy in Patients with Refractory Metastatic Renal Cell Carcinoma.
Hahn AW, Drake C, Denmeade SR, Zakharia Y, Maughan BL, Kennedy E, Link C Jr, Vahanian N, Hammers H, Agarwal N. Hahn AW, et al. Among authors: link c jr. Oncologist. 2020 Feb;25(2):121-e213. doi: 10.1634/theoncologist.2019-0599. Epub 2019 Sep 6. Oncologist. 2020. PMID: 32043778 Free PMC article. Clinical Trial.
456 results